• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Lipid self-assembling nanoparticles as a novel platform for mRNA-based vaccination.

Lipid self-assembling nanoparticles as a novel platform for mRNA-based vaccination.

Details
Files
DOI
10.48620/96057
Publisher DOI
10.1016/j.omtn.2026.102851
PubMed ID
41736889
Abstract
Synthetic messenger RNA (mRNA) formulated in lipid nanoparticles (mRNA-LNPs) is a promising candidate for next-generation gene therapy and genetic vaccines. However, mRNA-LNP formulations require low-temperature storage to ensure proper transport and distribution. Here, we introduce a lipid self-assembling nanoparticle (SANP) technology to address the stability challenges of mRNA-based therapeutics. SANP formulations can be prepared by simply mixing the components immediately before use, allowing mRNA vaccines to be stored and transported at 4°C without freezing, thereby enhancing their stability. SANPs loaded with mRNA (mRNA-SANPs) exhibited a sub-200 nm size, high mRNA encapsulation efficiency, colloidal stability post-assembly and in human plasma, and low hemolytic activity. Intramuscular (IM) and intravenous (IV) administration of mRNA-SANPs encoding a reporter gene in mice resulted in high levels of transgene expression, with no observed renal or hepatic toxicity and no release of pro-inflammatory cytokines. Additionally, protein fingerprint analysis of mRNA-SANPs in serum identified specific nanoparticle-protein interactions that correlated with in vivo biodistribution. Finally, mRNA-SANPs encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein elicited a significant immune response in mice following both IM and IV administration.[Figure: see text]De Rosa and colleagues demonstrate that self-assembling nanoparticles encapsulating mRNA induce the expression of mRNA-encoded proteins and an immune response in vivo. The on-demand preparation of the formulations enables storage of the mRNA vaccine at 4°C and overcomes some of the stability challenges faced by current mRNA-based formulations.
Date Issued
2026
Publication Type
Article
Subject(s)
500 Science > 540 Chemistry
600 Technology > 610 Medicine & health
Subjects
MT: Delivery Strategies
•
mRNA delivery
•
mRNA vaccine
•
self-assembling nanoparticles
•
protein corona
•
drug delivery
•
nanotechnology
Language(s)
en
Author(s)
De Chiara, Arianna
Nele, Valeria
Angelillo, Alessia
Campani, Virginia
Campanile, Andrea
Froechlich, Guendalina
Scognamiglio, Annagiulia
Pellino, Emilio
Greco, Antonietta
Chinello, Clizia
Pagani, Lisa
Eugster, Remo  
Department of Chemistry, Biochemistry and Pharmaceutical Sciences (DCBP)  
DCBP Gruppe Prof. Luciani  
Luciani, Paola  
DCBP Gruppe Prof. Luciani  
Corbo, Claudia
Nicosia, Alfredo
Sasso, Emanuele
De Rosa, Giuseppe
Additional Credits
DCBP Gruppe Prof. Luciani  
Department of Chemistry, Biochemistry and Pharmaceutical Sciences (DCBP)  
Journal
Molecular Therapy: Nucleic Acids
Publisher
Cell Press
ISSN
2162-2531
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 0eaa7c [ 7.08. 11:06]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify